Loading…
Employees: 40
Size Shattuck Labs (STTK) is a United States Health Care company (Biotechnology) with a market value of $464M, the 2751st largest of 3,117 United States companies the cockpit tracks. Shares closed at $4.62 on 6 Nov 2026.
Performance Over six months the shares fell 32.5%, against -7.3% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue fell 66.6% over the last twelve months (peer median +0.2%); the operating margin is -5,570.6% (peer median -15.6%).
Valuation It trades at 258.1× enterprise value to sales against a peer median of 12.1× (2nd most expensive of 16).
Short interest Short interest is 10.4% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.00M | $1.00M | $5.72M | $1.66M | $652,000 |
| Revenue growth | — | -83% | +245% | +154% | — |
| Gross profit | -$2.56M | -$2.69M | $1.89M | -$2.38M | -$2.72M |
| EBITDA | -$52.1M | -$47.8M | -$76.5M | -$87.9M | -$100.0M |
| Net income | -$52.6M | -$48.8M | -$75.4M | -$87.3M | -$102M |
| Free cash flow | -$41.2M | -$40.0M | -$60.6M | -$81.6M | -$106M |
| Capital expenditure | $212,000 | $71,000 | $59,000 | $407,000 | $11.6M |
| Total debt | $2.67M | $2.42M | $3.41M | $4.20M | $4.90M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STTK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.4% | -13.9% | 8th lowest of 21 |
| 6-month return | -32.5% | -7.3% | 3rd lowest of 20 |
| Distance from 52-week high | -44.5% | -35.3% | 7th lowest of 21 |
| Revenue growth (TTM) | -66.6% | +0.2% | lowest of 15 |
| Operating margin | -5,570.6% | -15.6% | 2nd lowest of 16 |
| EV / Sales | 258.1× | 12.1× | 2nd most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | 258.1× | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $462M | -4% | +20% | -79% | 11.4× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 18.0× | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | 12.1× | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 2.5× | -14.9% | -36.1% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | 5.2× | 6.0% | -62.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $458M | +139% | n/a | n/a | n/a | n/a | n/a |
| TaiMed Biologics 4147.TWO | Taiwan | $454M | +10% | +4% | -30% | 22.4× | 31.8% | -3.3% |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 2.3× | 18.2% | +7.3% |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | 8,168.1× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 5.2× | 15.2% | +0.5% |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | 12.1× | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | 5.9× | n/a | n/a |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 12.7× | 5.8% | +70.5% |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | 28.3× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | 6.4× | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | 98.9× | n/a | n/a |